Here are the latest stories being discussed in biopharma today:

Cullinan Enters Lupus Space with $280M Investment

In a shift towards autoimmune therapies, Cullinan Therapeutics (formerly Cullinan Oncology) is investing $280 million in lupus research. By branching out from oncology to immunology, the company is joining a surge of biotech firms working on groundbreaking lupus treatments. Investors greeted the news and name change positively, with Cullinan shares surging almost 15% on Tuesday morning.

Boehringer Ingelheim Outlines Decade-long Plan to Surpass Bayer

Boehringer Ingelheim aims to overtake Bayer as Germany’s leading pharmaceutical company with a potent pipeline of projects for the next decade. Fueled in part by its diabetes and heart drug Jardiance, Boehringer plans to launch 25 new drugs by 2030 across central nervous system, oncology, cardio-renal-metabolic, and immunology sectors.

Intra-Cellular Sets Sight on Caplyta Label Expansion Following Depression Study Success

Caplyta, Intra-Cellular Therapies’ drug, significantly improved symptoms in a late-stage major depressive disorder trial. Already approved to treat schizophrenia and bipolar depression, this new use could see Caplyta become a pipeline-in-a-pill as it boosts the drug towards a potential $2 billion in peak sales.

Takeda Partners with Kumquat; IL-2 Biotech Raises $55M

In other news, pharmaceutical company Takeda has announced a new partnership with Kumquat, while IL-2 biotech has successfully raised $55 million. Further detail on these collaborations and investments is yet to be released.

FDA Grants Priority Review to Novartis’ Fabhalta

The IgAN treatment developed by Novartis, Fabhalta, has been granted priority review by the FDA following the demonstration of positive Ph3 data.

J&J Reports Q1 Pharma Sales Growth

Johnson & Johnson attributes its Q1 pharmaceutical sales growth primarily to Darzalex and Carvykti while planning to increase its focus on medical technology.

FDA to Ax Interchangeability Label for Biosimilars

The FDA has signaled its readiness to remove the interchangeability designation for biosimilars in a move designed to streamline the approval process.